Drugs / Fisetin
Fisetin
also known as
5-desoxyquercetin · C.i. 75620 · C.i. natural brown 1 · Fisidenolon 1521 · NSC-407010 · NSC-656275
Trials 22
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07025226 | Aug 2025 → Sep 2028 expected | glioma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06431932 | Mar 2026 → Dec 2028 expected | — | Ove Andersen | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04770064 | Jun 2023 → May 2024 | osteoarthritis, knee | Austin V Stone | Withdrawn | No outcome recorded Stop: Business |
| Phase 1/2 | NCT05025956 | Oct 2021 → Oct 2024 | — | Steadman Philippon Research Institute | Unknown | No outcome recorded |
| Phase 1/2 | NCT04815902 | May 2021 → Feb 2025 | osteoarthritis, knee | Steadman Philippon Research Institute | Unknown | No outcome recorded |
| Phase 214 trials · 1 missed | ||||||
| Phase 2 | NCT07676435 | Jun 2026 → Jun 2027 expected | — | Cedars-Sinai Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06399809 | Sep 2024 → Nov 2026 expected | intermittent vascular claudication, peripheral arterial disease | Northwestern University | Recruiting | No outcome recorded |
| Phase 2 | NCT06113016 | Jul 2024 → Jun 2028 expected | female breast carcinoma | Jonsson Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05758246 | Aug 2023 → Mar 2027 expected | infectious disease with sepsis, multiple organ dysfunction syndrome | University of Minnesota | Recruiting | No outcome recorded |
| Phase 2 | NCT05593588 | Apr 2023 → Dec 2026 expected | common variable immunodeficiency, interstitial lung disease | Avni Joshi | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05595499 | Mar 2023 → Aug 2027 expected | female breast carcinoma | Jonsson Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05416515 | Oct 2022 → Dec 2024 | carpal tunnel syndrome | Peter C. Amadio, M.D. | Completed | No outcome recorded |
| Phase 2 | NCT04537299 | Apr 2022 → Aug 2024 | COVID-19 | Mayo Clinic | Terminated | No outcome recorded |
| Phase 2 | NCT04771611 | Jul 2021 → Sep 2022 | COVID-19 | James L. Kirkland, MD, PhD | Completed | No outcome recorded |
| Phase 2 | NCT04476953 | Aug 2020 → Sep 2026 overdue | COVID-19 | Mayo Clinic | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04313634 | Jun 2020 → Jun 2023 | — | Sundeep Khosla, M.D. | Completed | Missed primary |
| Phase 2 | NCT03675724 | Nov 2018 → Nov 2026 expected | FRAXD syndrome | Mayo Clinic | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT03430037 | Feb 2018 → Nov 2026 expected | FRAXD syndrome | Mayo Clinic | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT03325322 | Jan 2018 → Jan 2027 | diabetes mellitus, diabetic kidney disease | Mayo Clinic | Suspended | No outcome recorded Stop: Business |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05505747 | Jul 2025 → Feb 2026 | — | Austin V Stone | Withdrawn | No outcome recorded Stop: Business |
| Phase 2/3 | NCT05482672 | Apr 2023 | depressive disorder, obesity disorder, osteoarthritis, knee | Cale Andrew Jacobs, PhD | Withdrawn | No outcome recorded Stop: Business |
| Phase 41 trial | ||||||
| Phase 4 | NCT06819254 | Dec 2025 → Dec 2026 expected | — | Wake Forest University Health Sciences | Recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT04733534 Comparator | Jun 2022 → Dec 2026 expected | childhood malignant neoplasm | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 24 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fisetin | “Fisetin 20/mg/kg/day, orally for 2 consecutive days, for 2 consecutive months.” NCT03430037 ↗ |
| Known as | 5-desoxyquercetin | ChEMBL registry synonym — accepted as the source's own label CHEMBL31574 ↗ |
| Known as | C.i. 75620 | ChEMBL registry synonym — accepted as the source's own label CHEMBL31574 ↗ |
| Known as | C.i. natural brown 1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL31574 ↗ |
| Known as | Fisidenolon 1521 | ChEMBL registry synonym — accepted as the source's own label CHEMBL31574 ↗ |
| Known as | NSC-407010 | ChEMBL registry synonym — accepted as the source's own label CHEMBL31574 ↗ |
| Known as | NSC-656275 | ChEMBL registry synonym — accepted as the source's own label CHEMBL31574 ↗ |
| Action | Deplete | “Fisetin eliminates cells that have undergone a process called senescence.” NCT05595499 ↗ |
| Modality | Small molecule | “Fisetin is a plant flavanol senolytic” NCT04770064 ↗ |
| Route | Oral | “single 2-day oral treatment regimen with fisetin or placebo” NCT03325322 ↗ |